Peter Anevski bought $3.0M of Progyny (PGNY)
Executed Dec 23 2024, disclosed Dec 26 2024, 3 days later.
Over the 21 trading sessions from the disclosed entry session (Dec 26 2024), the stock returned +63.7% (delay-adjusted); from the execution session (Dec 23 2024), +53.9%. Derived: entry at the session's open, exit at the close 20 sessions later.
Peter Anevski (CHIEF EXECUTIVE OFFICER) filed 1 Form 4 report in the trailing twelve months (1 purchase, 0 sales), most often in Progyny, Inc. (PGNY). Across 1 priced purchase filing, the average 21-session return was +12.2% from execution and +2.0% from disclosure (delay-adjusted; derived). The largest single filing was $1.9M of PGNY (79,500 sh × $24.29, as filed), executed Nov 13 2025.
Healthcare · Progyny, Inc., a benefits management company, provides fertility, family building, and women's health benefits solutions in the United Stat…
More Healthcare filings→ Insider filings, newest first→ View the original filing at www.sec.gov→79,500 sh × $24.29
Exec Nov 13 2025
Filed Nov 17 2025 · 8:22 AM ET